2021
DOI: 10.3390/jcm10235483
|View full text |Cite
|
Sign up to set email alerts
|

Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis

Abstract: (1) Background: The objective of this rapid review is to assess whether new potassium binders (NPBs) could enable the optimization of RAASi therapy more than usual care or placebo in patients with or at risk of heart failure and hyperkalemia. (2) Methods: We searched for RCTs that included patients with or at risk of hyperkalemia and patients treated with Patiromer or sodium zirconium cyclosilicate (ZSC). The comparators were placebo, usual care, and potassium binders with different doses or different treatmen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
17
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(19 citation statements)
references
References 34 publications
1
17
0
1
Order By: Relevance
“…Current guidelines highlight the role of PBs in managing HK and preventing its recurrence ( McDonagh et al, 2021 ; Heidenreich et al, 2022 ). Newer PBs may also permit the continuation or intensification of RAASi therapy ( Agarwal et al, 2021 ; Imamura et al, 2021 ; Montagnani et al, 2021 ; Williams et al, 2021 ; Esteban-Fernández et al, 2022 ), which will improve the outcome of HF patients, as suggested by the ESC guidelines ( McDonagh et al, 2021 ). However, at the time of this study, the PBs available in Japan were SPS and CPS.…”
Section: Discussionmentioning
confidence: 99%
“…Current guidelines highlight the role of PBs in managing HK and preventing its recurrence ( McDonagh et al, 2021 ; Heidenreich et al, 2022 ). Newer PBs may also permit the continuation or intensification of RAASi therapy ( Agarwal et al, 2021 ; Imamura et al, 2021 ; Montagnani et al, 2021 ; Williams et al, 2021 ; Esteban-Fernández et al, 2022 ), which will improve the outcome of HF patients, as suggested by the ESC guidelines ( McDonagh et al, 2021 ). However, at the time of this study, the PBs available in Japan were SPS and CPS.…”
Section: Discussionmentioning
confidence: 99%
“… 15 In addition, the effect of patiromer on MRA inhibitors optimization is supported by a recent meta-analysis. 40 …”
Section: Patiromermentioning
confidence: 99%
“…46 As a consequence, and differently from patiromer, no conclusive data are still available about RAAS inhibitors maximization using ZS-9. 40 …”
Section: Sodium Zirconium Cyclosilicate (Zs-9)mentioning
confidence: 99%
“…Связанная с повышенным риском неблагоприятных (в том числе фатальных) исходов гиперкалиемия становится все более распространенным явлением у пациентов ХСН отчасти иза увеличения частоты сопутствующих заболеваний, но, по-видимому, в большей степени из-за широкого применения комбинированной терапии нейрогуморальными модуляторами [144]. Назначение секвестрантов калия (например, патиромера или натрия циркония циклосиликата) повышает безопасность такой терапии и вероятность достижения целевых доз ингибиторов ренин-ангиотензин-альдостероновой системы [1,96,[145][146][147]. Приведет ли коррекция гиперкалиемии этими препаратами к улучшению клинических исходов у пациентов с ХСН еще предстоит определить [96].…”
Section: лечебные подходыunclassified